secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2023-08-15T23:59:59+00:00
Accession:  0001558370-23-014951
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path Q2 net loss $4.2M ($0.53/sh); positive AML Phase 2 data for prexigebersen
--------------------------------------------------------------------------------

- Net loss $4.2M ($0.53/sh) vs $3.0M ($0.42/sh) a year ago; R&D spend up to $3.1M from $1.9M.
- Cash $3.4M at June 30, down from $10.4M at Dec 31, 2022; operating cash burn $6.9M for H1 2023.
- Positive interim Phase 2 data for prexigebersen in AML: well-tolerated, compelling efficacy in newly diagnosed and relapsed/refractory patients.
- Company plans to file for regulatory designations to accelerate pathway for prexigebersen in AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023014951/0001558370-23-014951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023014951/bpth-20230815x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer